NFKB1 and prostate cancer: The anti-inflammatory agent, ibuprofen, has been shown to inhibit constitutive activation of NF-κB and IKKα in prostate cancer cells (Palayoor et al, 1999), and when combined with megestrol acetate produced an increase in body weight in gastrointestinal cancer patients (McMillan et al, 1999), while megestrol acetate alone produced a decrease in body weight.